1-4 of 4
Mark G. Frattini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab

Todd L. Rosenblat, Michael R. McDevitt, Jorge A. Carrasquillo, Neeta Pandit-Taskar, Mark G. Frattini, Peter G. Maslak, Jae H. Park, Dan Douer, Dragan Cicic, Steven M. Larson, David A. Scheinberg, Joseph G. Jurcic
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (10): 2030–2037.
https://doi.org/10.1158/1078-0432.CCR-21-3712
Published: 13 May 2022
View articletitled, Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab
Open the PDF for Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab in another window
Journal Articles

A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure

Amer M. Zeidan, Hanna A. Knaus, Tara M. Robinson, Andrea M.H. Towlerton, Edus H. Warren, Joshua F. Zeidner, Amanda L. Blackford, Amy S. Duffield, David Rizzieri, Mark G. Frattini, Yair M. Levy, Mark A. Schroeder, Anna Ferguson, Katherine E. Sheldon, Amy E. DeZern, Ivana Gojo, Steven D. Gore, Howard Streicher, Leo Luznik, B. Douglas Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3519–3527.
https://doi.org/10.1158/1078-0432.CCR-17-3763
Published: 31 July 2018
View articletitled, A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Open the PDF for A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure in another window
Includes: Supplementary data
Journal Articles

Abstract A28: Use of a high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory AML: Proof of concept and clinical implementation of precision medicine.

David Shum, Mark Heaney, Renier Brentjens, Peter Maslak, Joseph Jurcic, Hakim Djaballah, Mark G. Frattini
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17_Supplement): A28.
https://doi.org/10.1158/1557-3265.HEMMAL14-A28
Published: 19 August 2015
View articletitled, Abstract A28: Use of a high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory AML: Proof of concept and clinical implementation of precision medicine.
Journal Articles

Abstract B10: A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine

David Shum, Ruth Santos, Mark Heaney, Renier Brentjens, Peter Maslak, Todd Rosenblat, Joseph Jurcic, Hakim Djaballah, Mark G. Frattini
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (4_Supplement): B10.
https://doi.org/10.1158/1557-3265.PMS14-B10
Published: 13 February 2015
View articletitled, Abstract B10: A novel high-throughput screen of primary leukemia cells to personalize therapy for relapsed/refractory acute myeloid leukemia (AML): Proof of concept and clinical implementation of precision medicine